ApprovedFDA approval

Rasonque (daraxonrasib)

Revolution Medicines (RVMD)

Marketer take

A targeted option in metastatic pancreatic cancer, one of oncology's hardest-to-treat settings, so expect high oncologist attention and fast pathway reviews at cancer centers and community practices.

Sponsor company
Revolution Medicines (RVMD)
Indication
To treat metastatic pancreatic cancer
Therapeutic area
Oncology
Event
FDA approval
Date
Aug 26, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move